|
1
|
de Groen PC, Gores GJ, LaRusso NF,
Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med.
341:1368–1378. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu T, Han C, Lunz JG III, Michalopoulos G,
Shelhamer JH and Demetris AJ: Involvement of 85-kd cytosolic
phospholipase A(2) and cyclooxygenase-2 in the proliferation of
human cholangiocarcinoma cells. Hepatology. 36:363–373. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patel T: Worldwide trends in mortality
from biliary tract malignancies. BMC Cancer. 2:102002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shaib YH, Davila JA, McGlynn K and
El-Serag HB: Rising incidence of intrahepatic cholangiocarcinoma in
the United States: A true increase? J Hepatol. 40:472–477. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakeeb A, Pitt HA, Sohn TA, Coleman J,
Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ and Cameron
JL: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and
distal tumors. Ann Surg. 224:463–473. 1996.
|
|
6
|
Patel T: Increasing incidence and
mortality of primary intrahepatic cholangiocarcinoma in the United
States. Hepatology. 33:1353–1357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sahu S and Sun W: Targeted therapy in
biliary tract cancers-current limitations and potentials in the
future. J Gastrointest Oncol. 8:324–336. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi
M, Taki J, Aomatsu Y, Yoshimura A, Ko S, Kin T, Yagura K, et al:
Ki-ras mutations and p53 protein expressions in intrahepatic
cholangiocarcinomas: Relation to gross tumor morphology.
Gastroenterology. 109:1612–1617. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Furubo S, Harada K, Shimonishi T,
Katayanagi K, Tsui W and Nakanuma Y: Protein expression and genetic
alterations of p53 and ras in intrahepatic cholangiocarcinoma.
Histopathology. 35:230–240. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tannapfel A, Sommerer F, Benicke M,
Katalinic A, Uhlmann D, Witzigmann H, Hauss J and Wittekind C:
Mutations of the BRAF gene in cholangiocarcinoma but not in
hepatocellular carcinoma. Gut. 52:706–712. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu X, Kobayashi S, Qiao W, Li C, Xiao C,
Radaeva S, Stiles B, Wang RH, Ohara N, Yoshino T, et al: Induction
of intrahepatic cholangiocellular carcinoma by liver-specific
disruption of Smad4 and Pten in mice. J Clin Invest. 116:1843–1852.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Endo K, Yoon BI, Pairojkul C, Demetris AJ
and Sirica AE: ERBB-2 overexpression and cyclooxygenase-2
up-regulation in human cholangiocarcinoma and risk conditions.
Hepatology. 36:439–450. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugawara H, Yasoshima M, Katayanagi K,
Kono N, Watanabe Y, Harada K and Nakanuma Y: Relationship between
interleukin-6 and proliferation and differentiation in
cholangiocarcinoma. Histopathology. 33:145–153. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chabner BA: Early accelerated approval for
highly targeted cancer drugs. N Engl J Med. 364:1087–1089. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu T, Leng J, Han C and Demetris AJ: The
cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt
and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer
Ther. 3:299–307. 2004.PubMed/NCBI
|
|
16
|
Peng YC, Lin CL, Hsu WY, Chang CS, Yeh HZ,
Tung CF, Wu YL, Sung FC and Kao CH: Statins are associated with a
reduced risk of cholangiocarcinoma: A population-based case-control
study. Br J Clin Pharmacol. 80:755–761. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Andersen JB, Spee B, Blechacz BR, Avital
I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts
LR, et al: Genomic and genetic characterization of
cholangiocarcinoma identifies therapeutic targets for tyrosine
kinase inhibitors. Gastroenterology. 142:1021–1031e15. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: The Gene Ontology Consortium: Gene ontology: Tool for the
unification of biology. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szklarczyk D, Franceschini A, Kuhn M,
Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork
P, et al: The STRING database in 2011: Functional interaction
networks of proteins, globally integrated and scored. Nucleic Acids
Res. 39:(Database). D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
von Mering C, Jensen LJ, Snel B, Hooper
SD, Krupp M, Foglierini sM, Jouffre N, Huynen MA and Bork P:
STRING: Known and predicted protein-protein associations,
integrated and transferred across organisms. Nucleic Acids Res.
33:D433–D437. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kandoth C, Schultz N, Cherniack AD, Akbani
R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al:
Cancer Genome Atlas Research Network: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:112013. View Article : Google Scholar
|
|
25
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoo M, Shin J, Kim J, Ryall KA, Lee K, Lee
S, Jeon M, Kang J and Tan AC: DSigDB: Drug signatures database for
gene set analysis. Bioinformatics. 31:3069–3071. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lamb J, Crawford ED, Peck D, Modell JW,
Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et
al: The Connectivity Map: Using gene-expression signatures to
connect small molecules, genes, and disease. Science.
313:1929–1935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qin C, Zhang C, Zhu F, Xu F, Chen SY,
Zhang P, Li YH, Yang SY, Wei YQ, Tao L, et al: Therapeutic target
database update 2014: A resource for targeted therapeutics. Nucleic
Acids Res. 42(D1): D1118–D1123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Davis AP, Wiegers TC, Roberts PM, King BL,
Lay JM, Lennon-Hopkins K, Sciaky D, Johnson R, Keating H, Greene N,
et al: A CTD-Pfizer collaboration: Manual curation of 88,000
scientific articles text mined for drug-disease and drug-phenotype
interactions. Database (Oxford). 2013:bat0802013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Silsirivanit A, Sawanyawisuth K, Riggins
GJ and Wongkham C: Cancer biomarker discovery for
cholangiocarcinoma: The high-throughput approaches. J Hepatobiliary
Pancreat Sci. 21:388–396. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Massey AJ: Tumour growth environment
modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity.
Sci Rep. 6:358742016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang L, Feng S and Yang Y: Identification
of transcription factors (TFs) and targets involved in the
cholangiocarcinoma (CCA) by integrated analysis. Cancer Gene Ther.
23:439–445. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Seubwai W, Kraiklang R, Wongkham C and
Wongkham S: Hypoxia enhances aggressiveness of cholangiocarcinoma
cells. Asian Pac J Cancer Prev. 13:(Suppl):. 53–58. 2012.PubMed/NCBI
|
|
34
|
Borad MJ, Champion MD, Egan JB, Liang WS,
Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD,
et al: Integrated genomic characterization reveals novel,
therapeutically relevant drug targets in FGFR and EGFR pathways in
sporadic intrahepatic cholangiocarcinoma. PLoS Genet.
10:e10041352014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tongtawee T, Kaewpitoon SJ, Loyd R,
Chanvitan S, Leelawat K, Praditpol N, Jujinda S and Kaewpitoon N:
High expression of matrix metalloproteinase-11 indicates poor
prognosis in human cholangiocarcinoma. Asian Pac J Cancer Prev.
16:3697–3701. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Severino FE, Hasimoto CN, Rodrigues MAM,
Llanos JC and Reis PP: Integrative analysis of transcriptome and
microRNome profiles in cholangiocarcinoma. J Cancer Sci Ther.
09:580–588. 2017. View Article : Google Scholar
|
|
37
|
Navaneethan U, Lourdusamy V, Gk Venkatesh
P, Willard B, Sanaka MR and Parsi MA: Bile proteomics for
differentiation of malignant from benign biliary strictures: A
pilot study. Gastroenterol Rep (Oxf). 3:136–143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang QX, Cui JY, Ma H, Jia XM, Huang FL
and Jiang LX: Screening of potential biomarkers for
cholangiocarcinoma by integrated analysis of microarray data sets.
Cancer Gene Ther. 23:48–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Smith J, Tho ML, Xu N and Gillespie DA:
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and
cancer. Adv Cancer Res. pp. 73–112. 2010, View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bartek J and Lukas J: Chk1 and Chk2
kinases in checkpoint control and cancer. Cancer Cell. 3:421–429.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kuroki T, Tomioka T, Tajima Y, Inoue K,
Ikematsu Y, Ichinose K, Furui J and Kanematsu T: Detection of the
pancreas-specific gene in the peripheral blood of patients with
pancreatic carcinoma. Br J Cancer. 81:350–353. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nath A and Chan C: Genetic alterations in
fatty acid transport and metabolism genes are associated with
metastatic progression and poor prognosis of human cancers. Sci
Rep. 6:186692016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen Y and Li P: Fatty acid metabolism and
cancer development. Sci Bull (Beijing). 61:1473–1479. 2016.
View Article : Google Scholar
|
|
44
|
Sung J, Wang Y, Chandrasekaran S, Witten
DM and Price ND: Molecular signatures from omics data: From chaos
to consensus. Biotechnol J. 7:946–957. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhu P, Aliabadi HM, Uludağ H and Han J:
Identification of potential drug targets in cancer signaling
pathways using stochastic logical models. Sci Rep. 6:230782016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mann BS, Johnson JR, He K, Sridhara R,
Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S, et al:
Vorinostat for treatment of cutaneous manifestations of advanced
primary cutaneous T-cell lymphoma. Clin Cancer Res. 13:2318–2322.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Audeh MW, Carmichael J, Penson RT,
Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN,
Oaknin A, Loman N, et al: Oral poly(ADP-ribose) polymerase
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and
recurrent ovarian cancer: A proof-of-concept trial. Lancet.
376:245–251. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wood L: Sunitinib malate for the treatment
of renal cell carcinoma. Expert Opin Pharmacother. 13:1323–1336.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Roskoski R Jr: RAF
protein-serine/threonine kinases: Structure and regulation. Biochem
Biophys Res Commun. 399:313–317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ma J, Shi J, Zhao D, Cheng L, Wang W, Li
F, Jiang X and Jiang H: Raf kinase inhibitor protein inhibits
cholangiocarcinoma cell metastasis by downregulating matrix
metalloproteinase 9 and upregulating tissue inhibitor of
metalloproteinase 4 expression. Oncol Lett. 9:15–24. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dreyer C, Sablin MP, Bouattour M,
Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V,
Raymond E, et al: Disease control with sunitinib in advanced
intrahepatic cholangiocarcinoma resistant to
gemcitabine-oxaliplatin chemotherapy. World J Hepatol. 7:910–915.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Eckmann KR, Patel DK, Landgraf A, Slade
JH, Lin E, Kaur H, Loyer E, Weatherly JM and Javle M: Chemotherapy
outcomes for the treatment of unresectable intrahepatic and hilar
cholangiocarcinoma: A retrospective analysis. Gastrointest Cancer
Res. 4:155–160. 2011.PubMed/NCBI
|
|
53
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: ABC-02 Trial Investigators: Cisplatin plus gemcitabine
versus gemcitabine for biliary tract cancer. N Engl J Med.
362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Merla A, Liu KG and Rajdev L: Targeted
therapy in biliary tract cancers. Curr Treat Options Oncol.
16:482015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ruzzenente A, Fassan M, Conci S, Simbolo
M, Lawlor RT, Pedrazzani C, Capelli P, D'Onofrio M, Iacono C,
Scarpa A, et al: Cholangiocarcinoma heterogeneity revealed by
multigene mutational profiling: Clinical and prognostic relevance
in surgically resected patients. Ann Surg Oncol. 23:1699–1707.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Brandi G, Farioli A, Astolfi A, Biasco G
and Tavolari S: Genetic heterogeneity in cholangiocarcinoma: A
major challenge for targeted therapies. Oncotarget. 6:14744–14753.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Dana P, Vaeteewoottacharn K, Kariya R,
Matsuda K, Wongkham S and Okada S: Repurposing cimetidine for
cholangiocarcinoma: Antitumor effects in vitro and in vivo. Oncol
Lett. 13:1432–1436. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang B, Yang R, Wu Y, Li H, Hu Z, Chen Y
and Zou S: Sodium valproate inhibits the growth of human
cholangiocarcinoma in vitro and in vivo. Gastroenterol Res Pract.
2013:3745932013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kwee SA, Okimoto GS, Chan OTM, Tiirikainen
M and Wong LL: Metabolic characteristics distinguishing
intrahepatic cholangiocarcinoma: A negative pilot study of
(18)F-fluorocholine PET/CT clarified by transcriptomic analysis. Am
J Nucl Med Mol Imaging. 6:73–83. 2016.PubMed/NCBI
|
|
60
|
Yang SH, Lin HY, Chang VHS, Chen CC, Liu
YR, Wang J, Zhang K, Jiang X and Yen Y: Lovastatin overcomes
gefitinib resistance through TNF-α signaling in human
cholangiocarcinomas with different LKB1 statuses in vitro and in
vivo. Oncotarget. 6:23857–23873. 2015.PubMed/NCBI
|
|
61
|
Yang SH, Lin HY, Changou CA, Chen CH, Liu
YR, Wang J, Jiang X, Luh F and Yen Y: Integrin β3 and LKB1 are
independently involved in the inhibition of proliferation by
lovastatin in human intrahepatic cholangiocarcinoma. Oncotarget.
7:362–373. 2016.PubMed/NCBI
|
|
62
|
Kim BB, Kim M and Park JB: The effects of
lovastatin on the morphology, cell viability and differentiation of
stem cells derived from gingiva. Biomed Res (Aligarh).
28:4922–4927. 2017.
|
|
63
|
Ruff P, Chasen MR, Long JEH and van
Rensburg CE: A phase II study of oral clofazimine in unresectable
and metastatic hepatocellular carcinoma. Ann Oncol. 9:217–219.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Das AK: Anticancer effect of antimalarial
artemisinin compounds. Ann Med Health Sci Res. 5:93–102. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chariyalertsak S, Sirikulchayanonta V,
Mayer D, Kopp-Schneider A, Fürstenberger G, Marks F and
Müller-Decker K: Aberrant cyclooxygenase isozyme expression in
human intrahepatic cholangiocarcinoma. Gut. 48:80–86. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Verdina A, Cardillo I, Nebbioso A, Galati
R, Menegozzo S, Altucci L, Sacchi A and Baldi A: Molecular analysis
of the effects of piroxicam and cisplatin on mesothelioma cells
growth and viability. J Transl Med. 6:272008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chung KD, Jeong YI, Chung CW, Kim DH and
Kang DH: Anti-tumor activity of all-trans retinoic
acid-incorporated glycol chitosan nanoparticles against HuCC-T1
human cholangiocarcinoma cells. Int J Pharm. 422:454–461. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Petrick JL, Freedman ND, Graubard BI,
Sahasrabuddhe VV, Lai GY, Alavanja MC, Beane-Freeman LE, Boggs DA,
Buring JE, Chan AT, et al: Coffee consumption and risk of
hepatocellular carcinoma and intrahepatic cholangiocarcinoma by
sex: The liver cancer pooling project. Cancer Epidemiol Biomarkers
Prev. 24:1398–1406. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kennedy OJ, Roderick P, Buchanan R,
Fallowfield JA, Hayes PC and Parkes J: Coffee, including
caffeinated and decaffeinated coffee, and the risk of
hepatocellular carcinoma: A systematic review and dose-response
meta-analysis. BMJ Open. 7:e0137392017. View Article : Google Scholar : PubMed/NCBI
|
